<DOC>
	<DOCNO>NCT00724776</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics albinterferon alfa 2b ( alb-IFN ) single dose Japanese chronic hepatitis C patient</brief_summary>
	<brief_title>Albinterferon Alfa 2b Single Dose Japanese Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Have clinical diagnosis CHC establish basis detectable viral load measure serum HCV RNA test least 6 month screen period . Age 20 69 year Have compensate liver disease result screen laboratory assessment Evidence decompensated liver disease and/or liver cirrhosis . Body weight &lt; 50 kg . A history immunologically mediate disease . A history clinical evidence interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Chronic hepatitis C , Albinterferon alfa 2b , phase I , Japan</keyword>
</DOC>